Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRG-HN009 cisplatin schedule comparison with radiation in locoregionally advanced head and neck squamous cell carcinoma
2024-515237-15-00Phase 3Authorised
- Sponsor
- Cancer Trials Ireland
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of cisplatin in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Cancer Trials Ireland. Primary endpoints: Acute toxicity and Overall survival. Planned start Jan 2025; status: authorised.
02
Drugs
cisplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2024-515237-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515237-15-00.